ArticleMolecular therapy. Advances2026
Anion-exchange chromatography separates structurally heterogeneous and low-potency particles in adeno-associated virus manufacture.
Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant adeno-associated virus (rAAV) manufacturing generates various particles in addition to full particles (FPs), posing a significant challenge for downstream purification. In this study, we applied anion-exchange chromatography (AEX) to resolve such particles of rAAV followed by the characterization of three fractions including an unidentified fraction, termed P3, that elutes at higher salt concentrations. Unexpectedly, density gradient ultracentrifugation (DGUC) clarified that P3 contained both empty particles (P3E) and full particles (P3F). No variation in genome packaging was observed between FPs and P3F, whereas zeta potential measurement showed that P3E and P3F exhibited increased negative surface charge compared with empty particles (EPs) and FPs in the earlier fractions (P1 and P2), respectively. Further characterizations using biolayer interferometry revealed the externalization of the negatively charged N-terminal region in viral protein 1 (VP1) of P3F in P3. In addition, P3F exhibited slightly elevated levels of deamidation, a critical quality attribute associated with vector potency, resulting in their reduced transduction efficiency. Notably, such P3F were not separated by DGUC solely. Collectively, AEX provides an effective strategy for isolating high-quality FPs by removing not only EPs but also structurally altered FPs with reduced potency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.